Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
|
(e) |
Amendment of Compensatory Arrangements of Certain |
On February 16, 2017, the Compensation Committee and the Board of
Directors of Pulse Biosciences, Inc. (the Company) approved
increases to the annual base salaries and changes to the annual
incentive bonus targets for each of the Companys named executive
officers as set forth in the chart below. The bonus amounts will
be determined based upon achievement of annually designated
Company performance objectives, as determined by the Compensation
Committee in its sole discretion.These changes are effective as
of January 1,2017.
|
Named Executive Officer |
Title |
2017Base Salary Compensation |
2017 Target Incentive Amount (% of Base Salary) |
||
|
Darrin R. Uecker |
Chief Executive Officer |
$330,000 |
35% |
||
|
Brian B. Dow |
Senior Vice President and Chief Financial Officer |
$260,000 |
25% |
||
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes. Pulse Biosciences, Inc. (NASDAQ:PLSE) Recent Trading Information
Pulse Biosciences, Inc. (NASDAQ:PLSE) closed its last trading session down -0.11 at 13.83 with 309,876 shares trading hands.